Neurogen’s anti-fat pill deemed “safe” for now

Branford-based Neurogen Corp. said it has successfully completed the first phase of a clinical trial on humans of its in-the-works anti-fat pill called NGD-4715. The drug lowers appetite by blocking certain hormones, and in earlier clinical tests caused rodents to slim down. Neurogen officials said the drug was “safe and well-tolerated” in this initial human clinical trial, and that they plan to proceed soon with a Phase 2 clinical trial that will test NGD-4715’s effectiveness on obese humans.